Central obesity is known to be involved in benign prostatic hyperplasia (BPH). Some study reports that increased fat tissue can induce chronic prostatic inflammation and change of Estrogen Receptors(ERs) ratio which contribute to the development of BPH. To find out the detailed effect of obesity on the prostate, we investigated the expression of estrogen receptors, inflammatory related cytokines and proportion of fatty acid in the prostate using a high-fat diet-induced obesity rat model. METHODS: Male Wistar rats (8 weeks old) were divided into a normal diet group (ND, n¼4) or a high fat diet group (HFD, n¼4). The ND formula contained 5% fat, meanwhile the HFD contained 32% fat. The rats were maintained on these diets for 16 weeks. After cystometry, the lateral prostate was harvested for analysis of related mRNA and protein expression, and proportion of fatty acid.
INTRODUCTION AND OBJECTIVES:
The assessment of prostatic inflammation is not standardized; thus, prostatic inflammation has been assessed by various methods in past reports. Research on prostatic inflammation has mainly focused on the magnitude of inflammation; however, the anatomical location of prostatic inflammation has not received much attention. In the present study, we examined the relationship between the grade, extent and location of the prostatic inflammation and clinical findings including UDS parameters.
METHODS: Tissue specimens obtained from 179 BPH patients who underwent TURP or HoLEP were stained with hematoxylin and eosin. Chronic prostatic inflammation was assessed by the grade (lymphocyte density) and extent (lymphocyte distribution) and location of inflammation. Each type of inflammatory finding was evaluated in relation to the following clinical parameters: age, prostate volume, PSA, BMI, the frequency of acute urinary retention (AUR) episodes, IPSS, urodynamic study.
RESULTS: he magnitude and extent of inflammation were not associated with any clinical parameters. We classified BPH patients into two groups according to the dominant location of inflammation, stromal and non-stromal. The prostatic volume of the stromal group was larger than that of the non-stromal group (63.8 vs 53.8 mL; p¼0.032). AUR episodes were more frequent in the stromal group (36.1% vs 11.4%; p¼0.006). Storage parameters (i.e. maximum cystometric capacity) on urodynamic study were not significantly different between the two groups. On the other hand, voiding parameters, i.e., max Pdet, Pdet at Qmax and BOOI, were significantly different between the two groups (116.8 vs 94.5 cmH2O, p¼0.014; 95.8 vs 75.4 cmH2O, p¼0.014; and 78.5 vs 56.3, p ¼0.014). The Qmax of the stromal group was significantly lower than that of the non-stromal group (7.3 vs 9.8 mL/sec, p¼0.004).
CONCLUSIONS: We demonstrated that prostatic stromal inflammation was associated with lower urinary tract dysfunction, particularly with BOO. These findings suggest that the location of prostatic inflammation (i.e., stromal vs. non-stromal) is one of the important factors determining the severity of LUTS.
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MP45-05 GROWTH HORMONE-RELEASING HORMONE (GHRH) ANTAGONISTS INHIBIT PROSTATIC ENLARGEMENT AND INFLAMMATION IN ?-CARRAGEENAN-INDUCED EXPERIMENTAL PROSTATITIS
Petra Popovics*, Ferenc G. Rick, Rhenzi Cai, Wei Sha, Andrew V. Schally, Miami, FL INTRODUCTION AND OBJECTIVES: The pathogenesis of benign prostatic hyperplasia (BPH) is associated with chronic inflammatory processes, but the complex molecular mechanism is not entirely explored. Our previous studies demonstrated that prostatic levels of GHRH are increased in experimental models of prostate cancer, BPH, and autoimmune prostatitis whereas GHRH antagonists exert multiple anti-proliferative and anti-inflammatory effects in these tissues. Our current study tests whether GHRH antagonists confer beneficial effects on chronic prostatic inflammation in rats.
METHODS: Chronic inflammation was induced in SpragueDawley rats by two intraprostatic injections of 3% l-carrageenan into both right and left ventral lobes, three weeks apart. GHRH antagonist, MIA-690, was administered 5 days after the second intraprostatic injection at 20 mg daily dose for 4 weeks. Prostates were processed for e598 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 
